AI-CVD vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung Corporation

EchoNext

by Pathway Labs

AI Verdict

AI-CVD and EchoNext are adjacent competitors, both focused on early detection of cardiovascular disease but utilizing different diagnostic modalities. AI-CVD leverages existing CT scans for opportunistic screening, providing comprehensive anatomical and density-based measurements. In contrast, EchoNext analyzes standard ECGs to identify hidden structural heart disease, offering a non-invasive and widely accessible screening method.

Choose AI-CVD if…

Choose AI-CVD if your primary goal is comprehensive, opportunistic screening for a wide range of cardiovascular and multisystem diseases using existing CT scans. This tool is ideal for identifying hidden health risks like coronary artery calcium, aortic calcification, cardiac chamber volumetry, and epicardial fat volumetry without requiring additional imaging or disrupting workflow. It's particularly well-suited for leveraging already acquired chest and abdominal CT scans to gain deeper insights into a patient's cardiovascular health and predict risks for conditions such as heart failure, atrial fibrillation, and stroke.

View AI-CVD →

Choose EchoNext if…

Choose EchoNext if you need an efficient and accessible AI-powered screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard 12-lead ECGs. This tool is excellent for early detection in broad patient populations, especially in primary care or community settings where echocardiography access might be limited. EchoNext can help identify patients who should be referred for further evaluation with an echocardiogram, potentially leading to earlier intervention and improved outcomes.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext analyzes standard 12-lead ECGs, which are routine, inexpensive, and widely available, making it easily integrable into existing clinical workflows. AI-CVD, while opportunistic, relies on existing CT scans, which may not be as universally available or routinely performed for initial cardiovascular screening as ECGs.

Clinical Value

EchoNext

EchoNext has demonstrated high accuracy in detecting a range of structural heart problems, outperforming cardiologists in head-to-head comparisons, and has been credited with guiding care that led to a heart transplant. While AI-CVD offers comprehensive opportunistic screening, the direct comparative clinical outcomes and impact on patient management are less explicitly detailed in the provided information.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, allowing for clear cost assessment. AI-CVD's pricing is 'contact for pricing,' which offers no immediate transparency for potential buyers.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a strong existing infrastructure for broad deployment and integration within healthcare systems. AI-CVD is cloud-deployed and FDA-cleared, but its integration pathways and scalability across large enterprise environments are not as explicitly detailed.

Innovation

Tie

Both tools represent significant innovation in cardiovascular AI. AI-CVD innovates by performing opportunistic multi-system screening from existing CT scans, extracting hidden health risks without additional procedures. EchoNext innovates by using standard ECGs to detect hidden structural heart disease, a capability previously thought impossible from ECG data alone.

Support & Docs

Tie

Both tools are FDA-cleared, implying a level of documentation and regulatory support. However, specific details regarding ongoing customer support, technical documentation, training resources, or community forums are not provided for either tool in the given information or web searches, making a definitive distinction impossible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	EchoNext
Name	AI-CVD	EchoNext
Company	HeartLung Corporation	Pathway Labs
Description	FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring AI-CVD and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for a physician?

AI-CVD is designed for opportunistic screening using existing CT scans, working in the background to identify various incidental findings that can enhance preventive medicine. EchoNext integrates directly with the OpenEvidence clinical decision support platform, which many physicians already use, embedding its screening outputs into common clinical workflows without requiring a separate system.

What is the depth of EHR integration for each tool, and how does it impact data flow?

While the specific depth of EHR integration for AI-CVD isn't detailed, AI-powered clinical decision support systems generally aim to streamline physician workflows by leveraging available clinical, laboratory, or imaging data from EHRs. EchoNext's integration with OpenEvidence means its screening output is available within a platform that can synthesize medical literature and potentially offer real-time documentation capabilities, suggesting a level of data flow that supports clinical decision-making.

What are the reported accuracy and sensitivity metrics for detecting cardiovascular diseases with each tool?

EchoNext has demonstrated high accuracy, correctly identifying 77% of structural heart problems from ECGs alone in a 2025 study, outperforming cardiologists who were 64% accurate. In internal tests, EchoNext achieved an area under the receiver operating characteristic curve (AUROC) of 85% and 78-80% in external validation. For AI-CVD, studies on a novel AI-based CVD Risk Score (which AI-CVD is based on) showed an AUC of 0.853, with sensitivity ranging from 61.31u201390.04% and accuracy of 80.15%.

Which cardiovascular specialties are these tools best suited for, and what specific clinical insights do they provide?

AI-CVD is suited for Cardiology, Pulmonology, and Radiology, offering automated CT-derived measurements for opportunistic screening of cardiovascular and multisystem diseases. It provides insights into coronary artery calcium scoring, aortic and mitral valve calcium, cardiac chamber volumetry, epicardial fat, and aorta/pulmonary artery sizing, extending to predict heart failure, atrial fibrillation, stroke, and overall CVD risk. EchoNext is designed for Cardiology, Family Medicine, Hospital Medicine, and Internal Medicine, analyzing ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension indicators.

What is the typical learning curve for physicians to effectively utilize each tool in their practice?

While specific learning curve details are not provided for either tool, AI tools integrated into clinical workflows generally aim to be intuitive and enhance user trust. The integration of EchoNext into the OpenEvidence platform suggests an effort to make it accessible within existing physician tools, potentially reducing the learning curve. AI-CVD's function as an opportunistic screening platform working in the background may also suggest a design focused on minimal workflow disruption.

What kind of customer support and resources are available to physicians for ongoing use and troubleshooting?

The provided information does not detail specific customer support or resource availability for either AI-CVD or EchoNext. However, successful integration of AI tools in healthcare often relies on robust support, including education and training for physicians.

What audit-trail features do these tools offer to ensure transparency and accountability in AI-assisted diagnoses?

The provided information does not explicitly detail audit-trail features for either AI-CVD or EchoNext. However, transparency and ethics are important concerns in the integration of AI tools in healthcare, and it is crucial that processes involved are clear and well-communicated. The need for continuous validation and recalibration of AI models to ensure reliability and adaptability also implies a need for tracking and auditing their performance.